Supplementary Material for: Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life

Splenic marginal zone lymphoma (SMZL) is a rare lymphoma belonging to the marginal zone lymphoproliferative disorders. Usually, SMZL occurs with indolent presentation and, when required, the standard of care is represented by rituximab-based regimens. No direct comparison of different rituximab-based combinations and polychemotherapy regimens has been conducted to date. In a monocentric cohort of 68 SMLZ patients, we showed that rituximab in monotherapy or in combination with bendamustine, compared with rituximab associated with the polychemotherapy cycle cyclophosphamide, hydroxydaunorubicin, vincristine and prednisolone (CHOP), resulted in a higher 5-year progression-free survival (91.3 ± 9% and 75 ± 15.7% vs. 30.8 ± 12.1%, <i>p</i> &lt; 0.001). Platelets at diagnosis &lt;100 ×10⁹/L (<i>p</i> = 0.034, HR = 4.3) and transformation into diffuse large B-cell lymphoma (<i>p</i> = 0.031, HR = 4.3) were associated with a lower overall survival.

脾边缘区淋巴瘤（Splenic marginal zone lymphoma, SMZL）是一类罕见的淋巴瘤，归属于边缘区淋巴增殖性疾病（marginal zone lymphoproliferative disorders）范畴。通常情况下，SMZL呈惰性病程表现，若需启动治疗，临床标准治疗方案以利妥昔单抗（rituximab）为基础。截至目前，尚未开展不同利妥昔单抗联合方案与多药化疗方案的头对头比较研究。本研究针对68例SMZL患者的单中心队列分析显示，与利妥昔单抗联合环磷酰胺、羟柔红霉素、长春新碱及泼尼松（CHOP）方案相比，利妥昔单抗单药或联合苯达莫司汀（bendamustine）治疗的5年无进展生存期（progression-free survival）更优（分别为91.3±9%、75±15.7% vs 30.8±12.1%，*p*<0.001）。诊断时血小板计数<100×10^9/L（*p*=0.034，风险比Hazard Ratio, HR=4.3）以及向弥漫大B细胞淋巴瘤转化（*p*=0.031，风险比Hazard Ratio, HR=4.3）均与较差的总生存期（overall survival）显著相关。